Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXin WangDZDongfeng Zeng

Discussion

Loading...

Member takes

Overview

Retrospective study shows ixazomib maintenance improves response rates in newly diagnosed multiple myeloma, indicating effective long-term treatment.

Key Points

  • Evaluate the efficacy and safety of transitioning from daratumumab to ixazomib maintenance therapy in newly diagnosed multiple myeloma patients.
  • Multicenter, retrospective study of newly diagnosed multiple myeloma patients
  • Included patients who transitioned from daratumumab-based induction to ixazomib maintenance
  • Collected data on treatment details, response rates, progression-free survival, and adverse events
  • Median follow-up of 23 months; 2-year progression-free survival rate of 54.72%
  • Majority had high-risk cytogenetics and non-transplant eligibility
  • Post-treatment response rates improved: ≥ VGPR increased to 88.14% and ≥ CR to 59.32%

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1d0https://doi.org/10.1182/blood-2025-7517
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study2025
  2. 2P22 | WHEN TRIAL DESIGN MEETS APPROVED MAINTENANCE: A SINGLE-CENTER REAL-WORLD EXPERIENCE WITH DARA-VTD INDUCTION AND CONSOLIDATION FOLLOWED BY LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA2026
  3. 3In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China2025
  4. 4Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study2025
  5. 5Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China2025